MedTrace Logo

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

NCT02533375 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.

Conditions

  • Generalized Pustular Psoriasis (GPP)
  • Adalimumab
  • Japanese

Interventions

DRUG

Adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Anne Robinson, PharmD · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-28
Primary Completion
2016-09-15
Completion
2017-07-20

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02533375 on ClinicalTrials.gov